Serum nitric oxide levels and flow-mediated dilatation in patients with Sheehan syndrome and the effect of combination therapy consisting of L-thyroxine, prednisolone, and conjugated estrogen/medroxyprogesterone acetate.
Baseline and stimulated nitric oxide (NO) levels were higher, whereas baseline arterial diameter, FMD-stimulated NO increment, and arterial dilatation ratio were lower in Sheehan syndrome (SS) patients than in control subjects. After combination therapy consisting of prednisolone, L-thyroxine, and conjugated estrogen, baseline and stimulated NO levels of SS remained as high, but FMD-stimulated NO, NO increment ratio, and arterial dilatation ratio increased with treatment.
Bahceci
Mithat
M
Department of Endocrinology, Dicle University School of Medicine, Diyarbakir, Turkey. mbahceci@dicle.edu.tr
Pasa
Semir
S
Akay
Hatice O
HO
Tuzcu
Alpaslan
A
Tumer
Cemil
C
Gokalp
Deniz
D
D000328:Adult; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006940:Hyperemia / Q000503:physiopathology; D007018:Hypopituitarism / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood*; D011239:Prednisolone / Q000494:pharmacology / Q000627:therapeutic use*; D013974:Thyroxine / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014463:Ultrasonography; D014664:Vasodilation / Q000187:drug effects*
D004966:Estrogens, Conjugated (USP); D009569:Nitric Oxide; D011239:Prednisolone; D017258:Medroxyprogesterone Acetate; D013974:Thyroxine